News | Clinical Decision Support | July 15, 2016

NCCN Accepted as CMS-Approved Provider-Led Entity for Development of Imaging Appropriate Use Criteria

NCCN joins 10 other multidisciplinary organizations as a qualified provider-led entity under the Medicare Appropriate Use Criteria (AUC) program for advanced diagnostic imaging

The National Comprehensive Cancer Network (NCCN), an alliance of 27 of the nation’s leading cancer centers, has been recognized as a qualified provider-led entity (PLE) for the new Medicare Appropriate Use Criteria (AUC) Program by Centers for Medicare & Medicaid Services (CMS). Through this qualification, CMS — the nation’s largest health payer — recognizes NCCN as a group qualified to develop AUC and establish policy and decision-making for diagnostic imaging in patients with cancer. NCCN Imaging AUC are available free of charge to registered users of NCCN.org and can be accessed at NCCN.org/ImagingAUC.

“NCCN is proud of this acknowledgement from CMS, and we congratulate our fellow PLEs on their recognition,” said Robert W. Carlson, M.D., chief executive officer, NCCN. “At NCCN, we strive to improve the lives of people with cancer, and as a CMS-approved provider-led entity for development of diagnostic imaging AUC, we help to further assure that patients with cancer receive quality care while avoiding unnecessary diagnostic imaging.”

Adapted from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), NCCN Imaging AUC support clinical decision-making around the use of imaging in patients with cancer by outlining all imaging procedures recommended in the NCCN Guidelines, including radiographs, computed tomography (CT) scans, magnetic resonance imaging (MRI), functional nuclear medicine imaging (PET, SPECT), and ultrasound. NCCN is committed to assuring that the most up-to-date recommendations are available and reviews and updates the NCCN Imaging AUC™ on a continual basis to ensure that the recommendations take into account the most current evidence.

Today, NCCN Imaging AUC for the following NCCN Guidelines are available:
• Acute Lymphoblastic Leukemia, Version 1.2016
• Acute Myeloid Leukemia, Version 1.2016
• Bladder Cancer, Version 2.2016
• Breast Cancer, Version 2.2016
• Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2016
• Genetic/Familial High-Risk Assessment: Colorectal, Version 1.2016
• Hodgkin Lymphoma, Version 3.2016
• Lung Cancer Screening, Version 2.2016
• Neuroendocrine Tumors, Version 2.2016
• Pancreatic Adenocarcinoma, Version 1.2016
• Prostate Cancer, Version 3.2016
• Prostate Cancer Early Detection, Version 2.2016
NCCN Imaging AUC for additional cancer types will be published in the coming months.

NCCN Guidelines are the recognized standard for clinical policy in cancer care and are the most thorough and frequently updated clinical practice guidelines available in any area of medicine. Since June 2008, CMS has recognized the NCCN Drugs & Biologics Compendium (NCCN Compendium) as a mandated reference for establishment of coverage policy and coverage decisions regarding the use of drugs and biologics in cancer care.

For more information: NCCN.org/ImagingAUC

Related Content

Videos | Image Guided Radiation Therapy (IGRT) | October 15, 2018
Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute, describes the benefits the departm
Varian Expands Cancer Care Portfolio With Noona Healthcare Acquisition
News | Patient Engagement | October 15, 2018
Varian announced the acquisition of privately-held software company Noona Healthcare, developer of a cloud-based,...
New Guideline for Prostate Cancer Supports Shortened Radiation Therapy
News | Prostate Cancer | October 12, 2018
Three prominent medical societies issued a new clinical guideline for physicians treating men with early-stage prostate...
Surgery, Radiation Therapy Equally Effective in Treating Oropharyngeal Cancer
News | Radiation Therapy | October 09, 2018
A new study by researchers at UT Southwestern Medical Center found no major long-term differences in the effectiveness...
ASTRO 2018 Radiation Therapy Clinical Trials
Feature | ASTRO | October 08, 2018
October 8, 2018 — The American Society for Radiation Oncology (ASTRO) announced the 10 top-rated clinical studies tha
Videos | Treatment Planning | October 08, 2018
Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology at Henry Ford Health System, descri
ViewRay and Miami Cancer Institute Host Symposium on MR-Guided Radiation Therapy
News | Image Guided Radiation Therapy (IGRT) | October 05, 2018
October 5, 2018 — Leading oncology experts from around the world recently met to discuss the integration of...
American College of Radiology Names 2019 Gold Medalists
News | Radiology Business | October 05, 2018
The American College of Radiology (ACR) Board of Chancellors (BOC) selected three innovators as 2019 Gold Medalists for...
Videos | Treatment Planning | October 05, 2018
Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology at Henry Ford Health System, descri
Videos | Image Guided Radiation Therapy (IGRT) | October 04, 2018
Carrie Glide-Hurst, Ph.D., and Benjamin Movsas, M.D., discuss Henry Ford Hospital's involvement in a national clinica